The role of cytotoxic and regulatory T cells in relapsed/refractory hodgkin lymphoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 18, Issue 3, 2010, Pages 206-211

  Koreishi, Aashiyana F ^a   Saenz, Adam J ^b   Persky, Dan O ^c   Cui, Hayan ^c   Moskowitz, Allison ^a   Moskowitz, Craig H ^a   Teruya Feldstein, Julie ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Biomarkers; Hodgkin lymphoma; Immunohistochemistry; Relapsed refractory

Indexed keywords

GRANZYME B; MEMBRANE PROTEIN; PROTEIN TIA 1; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CANCER RELAPSE; CELL FUNCTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

ADOLESCENT; ADULT; BIOPSY; DRUG RESISTANCE, NEOPLASM; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRANZYMES; HODGKIN DISEASE; HUMANS; IMMUNOCHEMISTRY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; POLY(A)-BINDING PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 77951759153     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181c7138b     Document Type: Article

References (29)

1. Poppema S, Van Den Berg A. Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol. 2000; 10:345-350.
2. Cools N, Ponsaerts P, Van Tendeloo VF, et al. Regulatory T cells and human disease. Clin Dev Immunol. 2007;2007:89195.
3. De Jong D, Enblad G. Inflammatory cells and immune microenvironment in malignant lymphoma. J Intern Med. 2008;264:528-536.
4. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009;9:15-27.
5. Oudejans JJ, Jiwa NM, Kummer JA, et al. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood. 1997; 89: 1376-1382.
6. Camilleri-Broet S, Ferme C, Berger F, et al. TiA1 in advanced-stage classical Hodgkin's lymphoma: no prognostic impact for positive tumour cells or number of cytotoxic cells. Virchows Arch. 2004; 445:344-346.
7. Alvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11: 1467-1473.
8. Asano N, Oshiro A, Matsuo K, et al. Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: a clinicopathologic study. J Clin Oncol. 2006;24: 4626-4633.
9. Kelley TW, Pohlman B, Elson P, et al. The ratio of FOXP3 regulatory T cells to granzyme B cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol. 2007;128:958-965.
10. Garcia JF, Camacho FI, Morente M, et al. Hodgkin and Reed- Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 2003;101:681-689.
11. Hedvat CV, Hegde A, Chaganti RS, et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol. 2002;33:968-974.
12. Hedvat CV, Jaffe ES, Qin J, et al. Macrophage-derived chemokine expression in classical Hodgkin's lymphoma: application of tissue microarrays. Mod Pathol. 2001;14:1270-1276.
13. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97:616-623.
14. Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol. 2004;124:645-652.
15. Chetaille B, Bertucci F, Finetti P, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood. 2009;113:2765-3775.
16. Schreck S, Friebel D, Buettner M, et al. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol. 2009;27:31-39.
17. Ishida T, Ishii T, Inagaki A, et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 2006;66:5716-5722.
18. Baumforth KR, Birgersdotter A, Reynolds GM, et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol. 2008;173:195-204.
19. Lamprecht B, Kreher S, Anagnostopoulos I, et al. Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood. 2008;112:3339-3347.
20. Juszczynski P, Ouyang J, Monti S, et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA. 2007;104:13134-13139.
21. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006; 108:804-811.
22. Curotto De Lafaille MA, Lafaille JJ. Natural and adaptive foxp3 regulatory T cells: more of the same or a division of labor? Immunity. 2009;30:626-635.
23. Shevach EM. Mechanisms of foxp3 T regulatory cell-mediated suppression. Immunity. 2009;30:636-645.
24. Zhou L, Chong MM, Littman DR. Plasticity of CD4 T cell lineage differentiation. Immunity. 2009;30:646-655.
25. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity. 2009; 30:656-665.
26. Waldmann H, Cobbold S. Regulatory T cells: context matters. Immunity. 2009;30:613-615.
27. Carreras J, Lopez-Guillermo A, Roncador G, et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol. 2009;27:1470-1476.
28. Badoual C, Hans S, Fridman WH, et al. Revisiting the prognostic value of regulatory T cells in patients with cancer. J Clin Oncol. 2009;27:e5-e6; author reply e7.
29. Mottet C, Golshayan D. CD4CD25Foxp3 regulatory T cells: from basic research to potential therapeutic use. Swiss Med Wkly. 2007;137:625-634.